NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

Summary

This study will be conducted to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of NTLA-3001 in adults with alpha-1 antitrypsin deficiency (AATD) -associated lung disease

Timeline

Start

2024-11-20

Primary completion

2025-01-09

Completion

2025-01-09

Outcome

Outcome not reported

Stopped: “Clinical trial ITL-3001-CL-101 for the investigational product NTLA-3001 was withdrawn due to prioritization of other Sponsor programs.”

Drugs

Indications